查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1916496

全球前列腺癌治疗市场：市场规模、份额、成长率、行业分析、按类型、应用和地区划分的考虑因素以及未来预测（2026-2034）

Prostate Cancer Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 请询问到货日

价格

摄护腺癌治疗市场成长因素

全球前列腺癌治疗市场是肿瘤领域成长最快的细分市场之一，其成长主要受男性老化导致前列腺癌发病率上升以及标靶治疗和精准医疗快速发展所驱动。预计到2025年，全球前列腺癌治疗市场规模将达到251.2亿美元。在诊断率不断提高和先进疗法广泛应用的推动下，预计到2026年，前列腺癌市场规模将增长至343.5亿美元，并在2034年进一步显着扩大至1068.6亿美元，在整个预测期内保持强劲的增长势头。

摄护腺癌主要影响老年男性，且大多数确诊病例发生在65岁及以上的族群。提高公众意识的宣传活动、常规前列腺特异性抗原（PSA）筛检以及医疗保健服务可近性的改善，都促进了诊断率的上升。因此，从荷尔蒙疗法到先进的标靶疗法和免疫疗法，全球对有效治疗方案的需求持续成长。

市场动态

推动市场扩张的关键因素是全球前列腺癌发生率的上升。根据世界癌症资料库，前列腺癌仍然是男性最常见的恶性肿瘤之一。早期诊断推广工作和宣传活动，例如一年一度的世界前列腺癌宣传活动，正在进一步推动治疗方案的普及。

然而，市场也面临诸多限制因素。荷尔蒙疗法的抗药性，尤其是去势抵抗性前列腺癌的出现，会降低长期治疗效果。此外，化疗和荷尔蒙疗法相关的副作用，例如疲劳、骨密度下降和代谢併发症，也会限制部分患者的治疗顺从性。

儘管存在这些挑战，但强大的研发投入正在为市场开闢新的成长途径。製药公司正致力于研发联合疗法，将雄性激素受体抑制剂 (ARI) 与 PARP 抑制剂、放射性配体疗法和雄性素剥夺疗法 (ADT) 结合，以克服抗药性并改善晚期疾病的治疗效果。

市场趋势

前列腺癌药物市场最显着的趋势之一是向标靶治疗和个人化医疗的转变。针对携带特定基因突变（例如 BRCA1 和 BRCA2）的患者设计的治疗方案正日益受到关注。放射性药物和精准肿瘤药物的核准数量不断增加，正在重塑治疗路径，尤其是在转移性去势抗性前列腺癌领域。

此外，口服药物製剂因其患者依从性更高、更容易长期疾病管理而日益普及，从而推动了市场份额的扩大。

依细分市场分析

依药物类别划分，雄性激素受体抑制剂占据最大的市场份额。这是因为它们能够抑制睪酮介导的癌症进展。预计到 2026 年，该细分市场将占总市场的 70% 以上，这反映了其作为晚期疾病一线治疗方案的地位。

按给药途径划分，口服疗法因其易用性和更高的依从性而占据主导地位，而肠外疗法在晚期和住院治疗中仍然发挥着重要作用。

按治疗类型划分，荷尔蒙疗法仍然是前列腺癌治疗的基石，其次是标靶治疗和免疫疗法。转移性去势抵抗性前列腺癌细分市场在所有疾病状态中占据最大份额，这主要归因于其高治疗需求和不断增加的核准疗法。

区域展望

北美地区预计将在 2025 年引领全球前列腺癌治疗市场，占据 51.37% 的市场份额，这得益于其先进的医疗保健基础设施、高诊断率以及对新型疗法的快速应用。 2025年，区域市场价值为129亿美元，预计2026年将成长至180.8亿美元。

欧洲是第二大区域市场，其成长主要得益于疾病盛行率的上升以及对创新癌症疗法的强有力的监管支持。亚太地区正在崛起为高成长区域，这得益于癌症发病率的上升、医疗保健覆盖范围的扩大以及全球和区域製药公司之间的战略联盟。

这份前列腺癌治疗市场报告对全球产业格局进行了全面深入的分析，重点在于2025年、2026年和2034年的市场规模、成长轨迹和竞争格局。本研究详细分析了影响全球前列腺癌治疗普及的关键参数，包括市场驱动因素、限制因素、机会、挑战和新兴趋势。

本报告从多个细分类别对市场进行评估，包括药物类别、给药途径、治疗类型、疾病状态和分销管道，以深入了解需求模式和治疗偏好。此外，报告还对北美、欧洲、亚太地区、拉丁美洲以及中东和非洲进行了全面的区域评估，揭示了各区域的市场规模、成长潜力和监管环境。

报告还包含广泛的竞争格局分析，概述了主要製药和生物製药公司及其产品组合、战略举措、研发管线和近期监管批准情况。报告还分析了 COVID-19 的影响、标靶和个人化治疗的进展以及向联合疗法的转变，从而全面展现了市场演变。

儘管治疗抗药性、治疗相关副作用和高昂成本等挑战依然存在，但对联合疗法、放射性药物和精准医疗的持续研究正在重塑治疗模式。北美凭藉其强大的医疗保健基础设施和对新型药物的快速应用，继续保持领先地位，而欧洲和亚太地区正在崛起为关键增长区域。总体而言，预计在报告涵盖的2025年、2026年和2034年期间，前列腺癌治疗市场仍将是全球癌症治疗行业中至关重要且快速发展的细分市场。

目录

第一章：引言

第二章：执行摘要

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键考虑因素

  • 全球市场主要趋势
  • 最新技术进展
  • 监理环境分析
  • 波特五力分析
  • 关税对市场的影响

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇

第四章主要发现

  • 主要国家和地区的摄护腺癌盛行率（2025 年）
  • 主要公司在研产品分析
  • 替代疗法概述
  • 市场主要新创企业
  • 主要公司新产品发布
  • 主要趋势：併购、合作等
  • 新冠疫情对市场的影响

第五章 全球前列腺癌药物市场分析：洞察与预测（2021-2034 年）

  • 市场分析、洞察与预测：依药物类别划分
    • 雄性激素受体抑制剂
    • 微管抑制剂
    • 促性腺激素释放激素 (GnRH) 激动剂
    • 促性腺激素释放激素 (GnRH) 受体拮抗剂
    • 其他
  • 市场分析、洞察与预测：依给药途径
    • 口服
    • 肠外给药
  • 市场分析、洞察与预测：按疗法
    • 化疗
    • 荷尔蒙单药治疗
    • 标靶治疗
    • 免疫治疗
  • 市场分析、洞察与预测：按适应症
    • 转移性去势抵抗性摄护腺癌
    • 非转移性去势抵抗性摄护腺癌
  • 市场分析、洞察与预测：依通路通路
    • 医院药房
    • 药局和零售药房
    • 线上药房
  • 市场分析、洞察与预测：按地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美前列腺癌药物市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章 欧洲前列腺癌药物市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 德国
    • 美国王国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚
    • 其他欧洲国家

第八章 亚太地区前列腺癌药物市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 东南亚
    • 其他亚太地区

第九章 拉丁美洲前列腺癌药物市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 其他拉丁美洲国家

第十章 中部东非与非洲前列腺癌药物市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 海湾合作委员会 (GCC)
    • 南非
    • 中东和非洲其他地区

第11章 竞争分析

  • 世界市场占有率分析(2025年)
  • 企业简介
    • Astellas Pharma Inc.
    • Pfizer Inc.
    • Johnson &Johnson Services, Inc.
    • Sanofi
    • Ferring Pharmaceuticals Inc.
    • Sumitomo Pharma Co., Ltd.(Myovant Sciences GmbH)
    • AbbVie Inc.
    • AstraZeneca
    • Tolmar, Inc.
    • Dendreon Pharmaceuticals LLC.
    • Bayer AG
Product Code: FBI112008

Growth Factors of prostate cancer therapeutics Market

The global prostate cancer therapeutics market represents one of the fastest-growing segments within the oncology landscape, driven by the rising incidence of prostate cancer among aging male populations and the rapid advancement of targeted and precision therapies. In 2025, the global prostate cancer therapeutics market was valued at USD 25.12 billion. With increasing diagnosis rates and wider adoption of advanced treatment modalities, the market is projected to grow to USD 34.35 billion in 2026 and further expand significantly to USD 106.86 billion by 2034, reflecting strong momentum throughout the forecast period.

Prostate cancer primarily affects older men, with a majority of diagnoses occurring in individuals aged 65 years and above. Rising awareness campaigns, routine prostate-specific antigen (PSA) screening, and improved access to healthcare services are contributing to higher diagnosis rates. As a result, demand for effective therapeutic options-ranging from hormone therapy to advanced targeted and immunotherapies-continues to accelerate globally.

Market Dynamics

A key driver supporting market expansion is the rising global prevalence of prostate cancer. According to global cancer databases, prostate cancer remains one of the most commonly diagnosed malignancies in men worldwide. Early diagnosis initiatives and awareness programs, such as annual global prostate cancer awareness campaigns, are further contributing to treatment adoption.

However, the market faces notable restraints. Resistance to hormone therapy, particularly the development of castration-resistant prostate cancer, reduces long-term treatment effectiveness. Additionally, adverse effects associated with chemotherapy and hormonal treatments-such as fatigue, bone density loss, and metabolic complications-can limit therapy continuation in some patients.

Despite these challenges, strong research and development investments are opening new growth avenues. Pharmaceutical companies are increasingly focusing on combination therapies, pairing androgen receptor inhibitors with PARP inhibitors, radioligand therapies, and androgen deprivation therapy to overcome resistance and improve outcomes in advanced disease stages.

Market Trends

One of the most prominent trends in the prostate cancer therapeutics market is the shift toward targeted and personalized medicine. Therapies designed for patients with specific genetic mutations, such as BRCA1 and BRCA2, are gaining traction. The increasing approval of radiopharmaceuticals and precision oncology drugs is reshaping treatment pathways, especially for metastatic castration-resistant prostate cancer.

Additionally, oral drug formulations are gaining preference due to better patient compliance and convenience in long-term disease management, contributing to their growing market share.

Segmentation Insights

By drug class, androgen receptor inhibitors account for the largest share of the market, supported by their effectiveness in blocking testosterone-driven cancer progression. In 2026, this segment is projected to hold over 70% of the total market share, reflecting its role as a first-line therapy in advanced cases.

By route of administration, oral therapies dominate due to ease of use and improved adherence, while parenteral therapies continue to play an important role in advanced and hospital-based treatment settings.

From a therapy perspective, hormonal therapy remains a cornerstone of prostate cancer management, followed by targeted therapy and immunotherapy. The metastatic castration-resistant prostate cancer segment represents the largest disease-state share, owing to its high treatment demand and increasing number of regulatory approvals.

Regional Outlook

North America dominated the global prostate cancer therapeutics market in 2025, accounting for 51.37% of total market share, supported by advanced healthcare infrastructure, high diagnosis rates, and rapid adoption of novel therapies. The regional market was valued at USD 12.9 billion in 2025 and increased to USD 18.08 billion in 2026.

Europe represents the second-largest regional market, driven by rising disease prevalence and strong regulatory support for innovative oncology drugs. Asia Pacific is emerging as a high-growth region, supported by increasing cancer incidence, expanding healthcare access, and strategic collaborations between global and regional pharmaceutical companies.

Competitive Landscape

The market is highly competitive, with leading pharmaceutical and biopharmaceutical companies actively investing in clinical trials, regulatory approvals, and strategic collaborations. Key players include Pfizer Inc., Johnson & Johnson Services, Inc., Astellas Pharma Inc., AstraZeneca, AbbVie Inc., and Bayer AG. Recent years have seen a surge in pipeline activity, particularly in radioligand therapies and next-generation targeted treatments, reinforcing long-term market expansion prospects.

Report Coverage

The prostate cancer therapeutics market report provides a comprehensive and in-depth analysis of the global industry landscape, focusing on market size, growth trajectory, and competitive dynamics in line with the report years 2025, 2026, and 2034. The study covers detailed insights across key parameters, including market drivers, restraints, opportunities, challenges, and emerging trends influencing the adoption of prostate cancer treatments worldwide.

The report evaluates the market across multiple segmentation categories such as drug class, route of administration, therapy type, disease state, and distribution channel, offering a granular understanding of demand patterns and treatment preferences. In addition, it presents a thorough regional assessment covering North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, highlighting region-wise market size, growth potential, and regulatory environments.

Furthermore, the report includes an extensive competitive landscape analysis, profiling leading pharmaceutical and biopharmaceutical companies, their product portfolios, strategic initiatives, pipeline developments, and recent regulatory approvals. The impact of COVID-19, advances in targeted and personalized therapies, and the shift toward combination treatments are also analyzed to provide a holistic view of the market's evolution.

Conclusion

The global prostate cancer therapeutics market is positioned for robust and sustained growth, supported by the rising prevalence of prostate cancer, increasing diagnosis rates, and continuous advancements in oncology drug development. With a market valuation of USD 25.12 billion in 2025, the expansion to USD 34.35 billion in 2026 reflects accelerating adoption of advanced hormonal, targeted, and immunotherapies. The projected growth to USD 106.86 billion by 2034 underscores the long-term significance of innovation-driven treatment strategies in prostate cancer care.

While challenges such as therapy resistance, treatment-related side effects, and high costs remain, ongoing research into combination therapies, radiopharmaceuticals, and precision medicine is reshaping the treatment paradigm. North America continues to dominate due to strong healthcare infrastructure and rapid uptake of novel drugs, while Europe and Asia Pacific are emerging as key growth regions. Overall, aligned strictly with the report years 2025, 2026, and 2034, the prostate cancer therapeutics market is expected to remain a critical and rapidly evolving segment within the global oncology industry.

Segmentation By Drug Class

  • Androgen Receptor Inhibitors
  • Microtubule Inhibitors
  • Gonadotropin Releasing Hormone (GnRH) Agonist
  • Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Therapy

  • Chemotherapy
  • Hormonal Therapy
  • Targeted therapy
  • Immunotherapy

By Disease State

  • Metastatic Castration-Resistant Prostate Cancer
  • Non-Metastatic Castration-Resistant Prostate Cancer

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Region

  • North America (By Drug Class, Route of Administration, Therapy Type, Disease State, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Drug Class, Route of Administration, Therapy Type, Disease State, Distribution Channel, and Country/Sub-Region)
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific (By Drug Class, Route of Administration, Therapy Type, Disease State, Distribution Channel, and Country/Sub-Region)
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, Route of Administration, Therapy Type, Disease State, Distribution Channel, and Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug Class, Route of Administration, Therapy Type, Disease State, Distribution Channel, and Country/Sub-Region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Prostate Cancer - by Key Countries/Regions, 2025
  • 4.2. Pipeline Analysis, by Key Players
  • 4.3. Overview of Alternative Therapies
  • 4.4. Key Start-ups in the Market
  • 4.5. New Product Launches, by Key Players
  • 4.6. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.7. Impact of COVID-19 on the Market

5. Global Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. Androgen Receptor Inhibitors
    • 5.1.2. Microtubule Inhibitors
    • 5.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 5.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Parenteral
  • 5.3. Market Analysis, Insights and Forecast - By Therapy
    • 5.3.1. Chemotherapy
    • 5.3.2. Hormonal Therapy
    • 5.3.3. Targeted therapy
    • 5.3.4. Immunotherapy
  • 5.4. Market Analysis, Insights and Forecast - By Disease State
    • 5.4.1. Metastatic Castration-Resistant Prostate Cancer
    • 5.4.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.5.1. Hospital Pharmacies
    • 5.5.2. Drug Stores & Retail Pharmacies
    • 5.5.3. Online Pharmacies
  • 5.6. Market Analysis, Insights and Forecast - Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. Androgen Receptor Inhibitors
    • 6.1.2. Microtubule Inhibitors
    • 6.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 6.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Parenteral
  • 6.3. Market Analysis, Insights and Forecast - By Therapy
    • 6.3.1. Chemotherapy
    • 6.3.2. Hormonal Therapy
    • 6.3.3. Targeted therapy
    • 6.3.4. Immunotherapy
  • 6.4. Market Analysis, Insights and Forecast - By Disease State
    • 6.4.1. Metastatic Castration-Resistant Prostate Cancer
    • 6.4.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.5.1. Hospital Pharmacies
    • 6.5.2. Drug Stores & Retail Pharmacies
    • 6.5.3. Online Pharmacies
  • 6.6. Market Analysis, Insights and Forecast - By Country
    • 6.6.1. U.S.
    • 6.6.2. Canada

7. Europe Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. Androgen Receptor Inhibitors
    • 7.1.2. Microtubule Inhibitors
    • 7.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 7.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Parenteral
  • 7.3. Market Analysis, Insights and Forecast - By Therapy
    • 7.3.1. Chemotherapy
    • 7.3.2. Hormonal Therapy
    • 7.3.3. Targeted therapy
    • 7.3.4. Immunotherapy
  • 7.4. Market Analysis, Insights and Forecast - By Disease State
    • 7.4.1. Metastatic Castration-Resistant Prostate Cancer
    • 7.4.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.5.1. Hospital Pharmacies
    • 7.5.2. Drug Stores & Retail Pharmacies
    • 7.5.3. Online Pharmacies
  • 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.6.1. Germany
    • 7.6.2. U.K.
    • 7.6.3. France
    • 7.6.4. Italy
    • 7.6.5. Spain
    • 7.6.6. Scandinavia
    • 7.6.7. Rest of Europe

8. Asia Pacific Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. Androgen Receptor Inhibitors
    • 8.1.2. Microtubule Inhibitors
    • 8.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 8.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Parenteral
  • 8.3. Market Analysis, Insights and Forecast - By Therapy
    • 8.3.1. Chemotherapy
    • 8.3.2. Hormonal Therapy
    • 8.3.3. Targeted therapy
    • 8.3.4. Immunotherapy
  • 8.4. Market Analysis, Insights and Forecast - By Disease State
    • 8.4.1. Metastatic Castration-Resistant Prostate Cancer
    • 8.4.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.5.1. Hospital Pharmacies
    • 8.5.2. Drug Stores & Retail Pharmacies
    • 8.5.3. Online Pharmacies
  • 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.6.1. China
    • 8.6.2. Japan
    • 8.6.3. India
    • 8.6.4. Australia
    • 8.6.5. Southeast Asia
    • 8.6.6. Rest of Asia Pacific

9. Latin America Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. Androgen Receptor Inhibitors
    • 9.1.2. Microtubule Inhibitors
    • 9.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 9.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Parenteral
  • 9.3. Market Analysis, Insights and Forecast - By Therapy
    • 9.3.1. Chemotherapy
    • 9.3.2. Hormonal Therapy
    • 9.3.3. Targeted therapy
    • 9.3.4. Immunotherapy
  • 9.4. Market Analysis, Insights and Forecast - By Disease State
    • 9.4.1. Metastatic Castration-Resistant Prostate Cancer
    • 9.4.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.5.1. Hospital Pharmacies
    • 9.5.2. Drug Stores & Retail Pharmacies
    • 9.5.3. Online Pharmacies
  • 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.6.1. Brazil
    • 9.6.2. Mexico
    • 9.6.3. Rest of Latin America

10. Middle East & Africa Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. Androgen Receptor Inhibitors
    • 10.1.2. Microtubule Inhibitors
    • 10.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 10.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 10.1.5. Others
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Oral
    • 10.2.2. Parenteral
  • 10.3. Market Analysis, Insights and Forecast - By Therapy
    • 10.3.1. Chemotherapy
    • 10.3.2. Hormonal Therapy
    • 10.3.3. Targeted therapy
    • 10.3.4. Immunotherapy
  • 10.4. Market Analysis, Insights and Forecast - By Disease State
    • 10.4.1. Metastatic Castration-Resistant Prostate Cancer
    • 10.4.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.5.1. Hospital Pharmacies
    • 10.5.2. Drug Stores & Retail Pharmacies
    • 10.5.3. Online Pharmacies
  • 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.6.1. GCC
    • 10.6.2. South Africa
    • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Astellas Pharma Inc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Pfizer Inc.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Johnson & Johnson Services, Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Sanofi
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Ferring Pharmaceuticals Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Sumitomo Pharma Co., Ltd. (Myovant Sciences GmbH)
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. AbbVie Inc.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. AstraZeneca
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Tolmar, Inc.
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Dendreon Pharmaceuticals LLC.
      • 11.2.10.1. Overview
      • 11.2.10.2. Products
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)
    • 11.2.11. Bayer AG
      • 11.2.11.1. Overview
      • 11.2.11.2. Products
      • 11.2.11.3. SWOT Analysis
      • 11.2.11.4. Recent Developments
      • 11.2.11.5. Strategies
      • 11.2.11.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 2: Global Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 3: Global Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy 2021-2034
  • Table 4: Global Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Disease State, 2021-2034
  • Table 5: Global Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 6: Global Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 7: North America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 8: North America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 9: North America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy 2021-2034
  • Table 10: North America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Disease State, 2021-2034
  • Table 11: North America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: North America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 13: Europe Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 14: Europe Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 15: Europe Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy 2021-2034
  • Table 16: Europe Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Disease State, 2021-2034
  • Table 17: Europe Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 18: Europe Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 19: Asia Pacific Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 20: Asia Pacific Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 21: Asia Pacific Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy 2021-2034
  • Table 22: Asia Pacific Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Disease State, 2021-2034
  • Table 23: Asia Pacific Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Asia Pacific Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 25: Latin America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 26: Latin America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 27: Latin America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy 2021-2034
  • Table 28: Latin America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Disease State, 2021-2034
  • Table 29: Latin America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 30: Latin America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 31: Middle East & Africa Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 32: Middle East & Africa Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 33: Middle East & Africa Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy 2021-2034
  • Table 34: Middle East & Africa Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Disease State, 2021-2034
  • Table 35: Middle East & Africa Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 36: Middle East & Africa Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Prostate Cancer Therapeutics Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 3: Global Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 4: Global Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2025 & 2034
  • Figure 5: Global Prostate Cancer Therapeutics Market Value Share (%), by Disease State, 2025 & 2034
  • Figure 6: Global Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 7: Global Prostate Cancer Therapeutics Market Value (USD billion), by Region, 2025 & 2034
  • Figure 8: North America Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 9: North America Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 10: North America Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 11: North America Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 12: North America Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 13: North America Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2025
  • Figure 14: North America Prostate Cancer Therapeutics Market Value (USD billion), by Disease State, 2025 & 2034
  • Figure 15: North America Prostate Cancer Therapeutics Market Value Share (%), by Disease State, 2025
  • Figure 16: North America Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 17: North America Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 18: North America Prostate Cancer Therapeutics Market Value (USD billion), By Country, 2025 & 2034
  • Figure 19: North America Prostate Cancer Therapeutics Market Value Share (%), By Country, 2025
  • Figure 20: Europe Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 21: Europe Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 22: Europe Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 23: Europe Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 24: Europe Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 25: Europe Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2025
  • Figure 26: Europe Prostate Cancer Therapeutics Market Value (USD billion), by Disease State, 2025 & 2034
  • Figure 27: Europe Prostate Cancer Therapeutics Market Value Share (%), by Disease State, 2025
  • Figure 28: Europe Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 29: Europe Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 30: Europe Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 31: Europe Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 32: Asia Pacific Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 33: Asia Pacific Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 34: Asia Pacific Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 35: Asia Pacific Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 36: Asia Pacific Prostate Cancer Therapeutics Market Value (USD billion),by Therapy, 2025 & 2034
  • Figure 37: Asia Pacific Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2025
  • Figure 38: Asia Pacific Prostate Cancer Therapeutics Market Value (USD billion), by Disease State, 2025 & 2034
  • Figure 39: Asia Pacific Prostate Cancer Therapeutics Market Value Share (%), by Disease State, 2025
  • Figure 40: Asia Pacific Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 41: Asia Pacific Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 42: Asia Pacific Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 43: Asia Pacific Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 44: Latin America Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 45: Latin America Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 46: Latin America Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 47: Latin America Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 48: Latin America Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 49: Latin America Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2025
  • Figure 50: Latin America Prostate Cancer Therapeutics Market Value (USD billion), by Disease State, 2025 & 2034
  • Figure 51: Latin America Prostate Cancer Therapeutics Market Value Share (%), by Disease State, 2025
  • Figure 52: Latin America Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 53: Latin America Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 54: Latin America Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 55: Latin America Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 56: Middle East & Africa Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 57: Middle East & Africa Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 58: Middle East & Africa Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 59: Middle East & Africa Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 60: Middle East & Africa Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 61: Middle East & Africa Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2025
  • Figure 62: Middle East & Africa Prostate Cancer Therapeutics Market Value (USD billion), by Disease State, 2025 & 2034
  • Figure 63: Middle East & Africa Prostate Cancer Therapeutics Market Value Share (%), by Disease State, 2025
  • Figure 64: Middle East & Africa Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 65: Middle East & Africa Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 66: Middle East & Africa Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 67: Middle East & Africa Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 68: Global Prostate Cancer Therapeutics Market Share (%), By Company, 2025